Clinical trial data for the vaccines show they were safe but did not generate enough of an immune response to effectively protect recipients against COVID-19.
While Merck is shelving its two vaccine candidates, the drugmaker said it will keep producing two drugs that treat COVID-19.
The drugmaker is continuing to produce MK-7110, which aims to modulate the respiratory system’s inflammatory response to COVID-19. Merck signed a $356 million agreement with the U.S. government Dec. 23 to supply up to 100,000 doses of MK-7110, and it is also continuing to produce MK-4482, an antiviral drug.
More articles on pharmacy:
FDA approves first monthly injectable to treat HIV
Amazon, Seattle health system create vaccination pop-up site
Premier, Pfizer partner to supply 5 critical drugs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
